Last kr0.86 SEK
Change Today +0.035 / 4.24%
Volume 5.2M
KARO On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 11:30 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

karo bio ab (KARO) Snapshot

Open
kr0.84
Previous Close
kr0.83
Day High
kr0.86
Day Low
kr0.83
52 Week High
03/19/14 - kr1.13
52 Week Low
12/17/14 - kr0.56
Market Cap
581.6M
Average Volume 10 Days
2.5M
EPS TTM
kr-0.09
Shares Outstanding
676.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KARO BIO AB (KARO)

Related News

No related news articles were found.

karo bio ab (KARO) Related Businessweek News

No Related Businessweek News Found

karo bio ab (KARO) Details

Karo Bio AB (publ), a pharmaceutical company, focuses on the research and development of drugs for unmet medical needs primarily in Sweden. The company is involved in the preclinical development of drugs primarily in the fields of neuropsychiatry, inflammation, autoimmune diseases, and cancer. Its pipeline products include nuclear receptor that regulates various functions in the body affecting a range of diseases, such as inflammation, diabetes, dyslipidemia and osteoporosis, obesity, and certain forms of cancer; estrogen receptor beta for use in the areas of women’s health, depression, and certain forms of cancer; and RORgamma for the treatment of autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, psoriasis, and multiple sclerosis. The company has collaboration agreements with Pfizer Inc. to discover and develop compounds for the treatment of autoimmune diseases; and 4D Science GmbH to develop treatments for fibrotic diseases. Karo Bio AB (publ) was founded in 1987 and is headquartered in Huddinge, Sweden.

24 Employees
Last Reported Date: 02/13/15
Founded in 1987

karo bio ab (KARO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

karo bio ab (KARO) Key Developments

Karo Bio Aktiebolag (publ) Reports Consolidated and Parent Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Karo Bio Aktiebolag (publ) reported consolidated and parent earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, on consolidated basis, the company reported net sales of SEK 8,062,000 compared to SEK 9,652,000 a year ago. Operating loss was SEK 21,822,000 compared to SEK 3,401,000 a year ago. Loss after financial items were SEK 21,779,000 compared to SEK 3,346,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 21,779,000 or SEK 0.03 per share compared to SEK 3,346,000 or SEK 0.01 per share a year ago. Cash used in operating activities was SEK 10,668,000 compared to SEK 7,860,000 a year ago. Net investment in equipment was SEK 12,000 against SEK 1,460,000 for the same period a year ago. For the year, on consolidated basis, the company reported net sales of SEK 30,060,000 compared to SEK 47,029,000 a year ago. Operating loss was SEK 59,455,000 compared to SEK 22,258,000 a year ago. Loss after financial items were SEK 59,282,000 compared to SEK 22,078,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 59,282,000 or SEK 0.09 per share compared to SEK 22,078,000 or SEK 0.04 per share a year ago. Cash used in operating activities was SEK 46,330,000 compared to SEK 33,389,000 a year ago. Net investment in equipment was SEK 1,483,000 compared to SEK 2,245,000 a year ago. For the quarter, on parent basis, the company reported net sales of SEK 8,062,000 compared to SEK 9,652,000 a year ago. Operating loss was SEK 21,821,000 compared to SEK 6,960,000 a year ago. Loss after financial items were SEK 21,734,000 compared to SEK 3,346,000 a year ago. Net loss for the period was SEK 21,734,000 compared to SEK 3,346,000 a year ago. For the year, on parent basis, the company reported net sales of SEK 30,060,000 compared to SEK 47,029,000 a year ago. Operating loss was SEK 59,543,000 compared to SEK 25,835,000 a year ago. Loss after financial items were SEK 59,281,000 compared to SEK 22,084,000 a year ago. Net loss for the period was SEK 59,281,000 compared to SEK 22,084,000 a year ago.

KaroBio AB Announces Executive Changes

KaroBio AB announced that Per Bengtsson, CEO has informed the board of directors that he wants to step down from his current position with immediate effect. Per Bengtsson has been working as CEO since 2011. The Board has decided to appoint Anders Lonner as executive chairman of the board. His prime goal will be to develop and complement company’s business platform with projects and products closer to the market. The company also announced that CFO Henrik Palm is appointed as Executive Vice President.

Karo Bio Aktiebolag (publ) Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Karo Bio Aktiebolag (publ) Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KARO:SS kr0.86 SEK +0.035

KARO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KARO.
View Industry Companies
 

Industry Analysis

KARO

Industry Average

Valuation KARO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KARO BIO AB, please visit www.karobio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.